USD 167.01
(-2.21%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | 3.68 Billion USD | 17.18% |
2022 | 3.35 Billion USD | 4.18% |
2021 | 3.17 Billion USD | 6.85% |
2020 | 2.68 Billion USD | 22.38% |
2019 | 2.45 Billion USD | 7.16% |
2018 | 2.21 Billion USD | 14.97% |
2017 | 1.94 Billion USD | 21.97% |
2016 | 1.63 Billion USD | 41.33% |
2015 | 868 Million USD | 2.74% |
2014 | 1.14 Billion USD | 14.96% |
2013 | 1.01 Billion USD | -16.29% |
2012 | 941 Million USD | 23.78% |
2011 | 635 Million USD | 72.29% |
2010 | 400 Million USD | 44.35% |
2009 | 2 Million USD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q1 | 927 Million USD | 11.02% |
2024 Q3 | 955 Million USD | 2.23% |
2024 Q2 | 1.03 Billion USD | 11.43% |
2023 Q1 | 818 Million USD | 18.38% |
2023 Q3 | 830 Million USD | -14.87% |
2023 Q4 | 835 Million USD | 0.6% |
2023 FY | - USD | 17.18% |
2023 Q2 | 975 Million USD | 19.19% |
2022 Q3 | 853 Million USD | -0.23% |
2022 Q4 | 691 Million USD | -18.99% |
2022 Q1 | 907 Million USD | 50.17% |
2022 FY | - USD | 4.18% |
2022 Q2 | 855 Million USD | -5.73% |
2021 Q3 | 845 Million USD | 0.84% |
2021 Q2 | 838 Million USD | -3.12% |
2021 Q1 | 865 Million USD | 38.62% |
2021 FY | - USD | 6.85% |
2021 Q4 | 604 Million USD | -28.52% |
2020 Q3 | 777 Million USD | 15.8% |
2020 FY | - USD | 22.38% |
2020 Q4 | 624 Million USD | -19.69% |
2020 Q1 | 657 Million USD | 19.24% |
2020 Q2 | 671 Million USD | 2.13% |
2019 Q4 | 551 Million USD | -19.44% |
2019 Q3 | 684 Million USD | 7.38% |
2019 FY | - USD | 7.16% |
2019 Q1 | 540 Million USD | 1.89% |
2019 Q2 | 637 Million USD | 17.96% |
2018 Q3 | 614 Million USD | 9.64% |
2018 Q2 | 560 Million USD | 14.52% |
2018 Q1 | 489 Million USD | -5.05% |
2018 FY | - USD | 14.97% |
2018 Q4 | 530 Million USD | -13.68% |
2017 Q4 | 515 Million USD | -3.38% |
2017 Q1 | 441 Million USD | 40.89% |
2017 FY | - USD | 21.97% |
2017 Q2 | 451 Million USD | 2.27% |
2017 Q3 | 533 Million USD | 18.18% |
2016 Q4 | 313 Million USD | -21.55% |
2016 FY | - USD | 41.33% |
2016 Q3 | 399 Million USD | 6.68% |
2016 Q2 | 374 Million USD | -6.03% |
2016 Q1 | 398 Million USD | 144.17% |
2015 FY | - USD | 2.74% |
2015 Q4 | 163 Million USD | -50.61% |
2015 Q3 | 330 Million USD | 16.61% |
2015 Q2 | 283 Million USD | 3.28% |
2015 Q1 | 274 Million USD | 28.04% |
2014 Q2 | 249 Million USD | -9.12% |
2014 Q1 | 274 Million USD | 32.37% |
2014 FY | - USD | 14.96% |
2014 Q4 | 214 Million USD | -24.91% |
2014 Q3 | 285 Million USD | 14.46% |
2013 Q1 | 236 Million USD | 14.56% |
2013 Q2 | 214 Million USD | -9.32% |
2013 FY | - USD | -16.29% |
2013 Q3 | 232 Million USD | 8.41% |
2013 Q4 | 207 Million USD | -10.78% |
2012 Q2 | 325 Million USD | 32.11% |
2012 Q3 | 281 Million USD | -13.54% |
2012 Q4 | 206 Million USD | -26.69% |
2012 FY | - USD | 23.78% |
2012 Q1 | 246 Million USD | 23.62% |
2011 Q4 | 199 Million USD | -27.11% |
2011 Q2 | 187 Million USD | -6.03% |
2011 FY | - USD | 72.29% |
2011 Q1 | 199 Million USD | 0.0% |
2011 Q3 | 273 Million USD | 45.99% |
2010 FY | - USD | 44.35% |
2009 FY | - USD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Amneal Pharmaceuticals, Inc. | 500.78 Million USD | -635.849% |
Bausch Health Companies Inc. | 2.88 Billion USD | -27.73% |
Catalent, Inc. | -284 Million USD | 1397.535% |
Emergent BioSolutions Inc. | -505.29 Million USD | 829.27% |
Elanco Animal Health Incorporated | -224 Million USD | 1745.089% |
Perrigo Company plc | 646.2 Million USD | -470.257% |
Teva Pharmaceutical Industries Limited | 4.33 Billion USD | 14.955% |